Israel's GHF Settles Drug Supply Debts
In Israel, the General Health Fund has reached a collective agreement with local manufacturers and importers by which it will settle all its debts to them. The settlement is apparently to be carried out with immediate effect, and involves a 10.5% discount.
However, the Marketletter's local correspondent points out, the agreement does not cover Teva (Marketletter January 1 & 8) and Agis, which have reached separate deals with the GHF. The GHF owed Agis NIS78.3 million.
Industry sources say the total settlement involves the payment of about NIS550 million (around $180 million), which represents about 36% of the total annual turnover in the Israeli market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze